Biohaven Stock Soars on Drug Trial Results: Time to Jump In?

Biohaven Today BHVN Biohaven $45.03 -0.91 (-1.98%) 52-Week Range $16.48 ▼ $62.21 Price Target $59.00 Add to Watchlist Biohaven Ltd. NYSE: BHVN has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinocerebellar ataxia (SCA). This rare and debilitating neurodegenerative disease currently lacks FDA-approved treatments. The news sent Biohaven shares soaring as high as 20% on Monday, marking a si ...